The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

Table 2 Participant characteristics for treatment cohort

Participant	Age	Sex	MS Phenotype	Duration of MS (years)	EDSS at entry	Clinical episode of optic neuritis	Optic nerve affected	Time elapsed since first clinical episode of optic neuritis (years)
1	44	Male	SPMS	19	6	Yes	Right	19
2	51	Male	SPMS	26	6	Yes	Both	26 (left); 9 (right)
3	40	Female	SPMS	13	6.5	No	Left*	6
4	48	Male	SPMS	27	6	Yes	Left	27
5	48	Male	SPMS	12	6.5	Yes	Right	11
6	52	Male	SPMS	18	6	Yes	Right	18 & 13
7	53	Female	SPMS	5	6	Yes	Left	6
8	51	Male	SPMS	7	5.5	Yes	Both	2 (left); 7 (right)
9	46	Female	SPMS	11	6	Yes	Both	5
10	51	Male	SPMS	6	6.5	Yes	Both	6

SPMS = secondary progressive multiple sclerosis, EDSS = expanded Kurtzke disability status scale. * First episode of Uhthoff's phenomenon 6 years prior to recruitment.

ISSN: 1745-6215